Pfizer has granted SatRx, a start-up company in the Russian ChemRar group, exclusive global rights, excluding China, to its DPP-IV (dipeptidyl peptidase-IV) inhibitor PF-00734200, which has been studied in Phase II trials for type 2 diabetes. SatRx will develop and commercialise PF-00734200 as a monotherapy and in combination with certain other classes of drugs. The deal follows on from a memorandum of understanding that the parties signed in 2011 to explore collaborations for the development of vaccines and therapies for cardiometabolic, infectious and oncology diseases in Russia and other countries.